Evidence map›Paper›PMID 29747035›Full record

ArticleNuclear medicine and biology2018

Microscale radiosynthesis, preclinical imaging and dosimetry study of [

Ksenia Lisova, Maxim Sergeev, Susan Evans-Axelsson, Andreea D Stuparu, Seval Beykan, Jeffrey Collins, Jason Jones, Michael Lassmann, Ken Herrmann, David Perrin and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nuclear medicine and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Preparation and Evaluation of [Molecules (Basel, Switzerland) · 2022
    Article
  3. Development of [Bioconjugate chemistry · 2022
    Article
  4. Article
  5. Article
  6. Optimization of Radiochemical Reactions using Droplet Arrays.Journal of visualized experiments : JoVE · 2021
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Ksenia LisovaPhysics in Biology and Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Maxim SergeevCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Susan Evans-AxelssonDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Andreea D StuparuDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Seval BeykanDepartment of Nuclear Medicine, University of Würzburg, Würzburg, Germany.
Jeffrey CollinsCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Jason JonesPhysics in Biology and Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Michael LassmannDepartment of Nuclear Medicine, University of Würzburg, Würzburg, Germany.
Ken HerrmannDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA.
David PerrinDepartment of Chemistry, University of British Columbia, Vancouver, BC, Canada.
Jason T LeeCrump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA. Electronic address: jasontlee@mednet.ucla.edu.
Roger SlavikDepartment of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Ahmanson Translational Imaging Division, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA. Electronic address: rslavik@mednet.ucla.edu.
R Michael van DamPhysics in Biology and Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center (JCCC), UCLA, Los Angeles, CA, USA. Electronic address: mvandam@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of Würzburg · DEUCLA Jonsson Comprehensive Cancer CenterUniversity of British Columbia · CA

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Institute for Molecular Medicine (IMED) CoreU54CA151819 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HEATH, JAMES R. · 2010 to 2014
$12.1M
Research Training in Biomedical PhysicsT32EB002101 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Michael F McNitt-Gray · 2003 to 2026
$5.3M
Automated microfluidic production of high specific activity PET tracers to enable routine CNS imagingR21AG049918 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2015 to 2017
$693k
Microliter radiosynthesizer for producing high specific activity PET ligandsR21EB015540 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VAN DAM, ROBERT MICHAEL · 2012 to 2013
$405k
NCI NIH HHS P30 CA016042NCI NIH HHS U54 CA151819NIA NIH HHS R21 AG049918NIBIB NIH HHS R21 EB015540NIBIB NIH HHS T32 EB002101
6 · The paper itself

Abstract

backgroundPeptides labeled with positron-emitting isotopes are emerging as a versatile class of compounds for the development of highly specific, targeted imaging agents for diagnostic imaging via positron-emission tomography (PET) and for precision medicine via theranostic applications. Despite the success of peptides labeled with gallium-68 (for imaging) or lutetium-177 (for therapy) in the clinical management of patients with neuroendocrine tumors or prostate cancer, there are significant advantages of using fluorine-18 for imaging. Recent developments have greatly simplified such labeling: in particular, labeling of organotrifluoroborates via isotopic exchange can readily be performed in a single-step under aqueous conditions and without the need for HPLC purification. Though an automated synthesis has not yet been explored, microfluidic approaches have emerged for

methodsBoth [

resultsThe micro-synthesis exhibited highly-repeatable performance with radiochemical conversion of 50 ± 6% (n = 15), overall decay-corrected radiochemical yield of 16 ± 1% (n = 5) in ~40 min, radiochemical purity >99%, and high molar activity. Preclinical imaging with [

conclusionsThe combination of novel chemical approaches to

Indexed as

Fluorine RadioisotopesLab-On-A-Chip DevicesPositron Emission Tomography Computed TomographyAnimalsBoron CompoundsCell Line, TumorMiceOctreotideRadioactive TracersRadiochemistryRadiometryReceptors, SomatostatinAMBF3-TATEBoron CompoundsFluorine-18Fluorine RadioisotopesOctreotideRadioactive TracersReceptors, SomatostatinClinical translationMicrofluidic radiochemistryNeuroendocrine tumorsSSTR2 imagingTrifluoroborateTumor-targeting peptide

Identifiers

PMID29747035
PMCPMC6015542
OpenAlexW2801257057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.